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Abstract
Lipoprotein(a) [Lp(a)] consists of a low-density lipoprotein (LDL)-like core and
apo(a), a large molecular weight glycoprotein. Apo(a) is highly homologous to plas‐
minogen, yet in contrast exhibits a unique size polymorphism that is characterized by
an increasing number of kringle-IV (K-IV) repeats. The number of K-IV repeats ranges
from n = 2 to n = 40 or even higher. Apo(a) is synthesized almost exclusively in the
liver and there is still some debate whether the assembly of Lp(a) from LDL and
apo(a) occurs inside the liver cells or in the circulating blood. The plasma Lp(a) con‐
centration is markedly skewed reaching from <1 mg/dl up to >200 mg/dl. The plasma
concentration is >90% genetically determined and correlates negatively with the num‐
ber of K-IV repeats. In the apo(a) promoter, there are numerous response elements for
transcription factors and nuclear receptors that regulate apo(a) expression. The
HNF4α binding sequence appears to be the most important one in that respect, yet
further work needs to be done to unravel the key features of apo(a) biosynthesis un‐
der different conditions. Importantly, activation of FXR causes the dissociation of
HNF4α α from its response element and in turn a significant downregulation of
apo(a) transcription.
Undoubtedly, Lp(a) is one of the most atherogenic lipoproteins and recent large epi‐
demiological studies document quite impressively that Lp(a) is an independent causal
risk factor for coronary heart disease (CHD) and myocardial infarction. This fact led
to the development of specific medications to reduce Lp(a) in patients with high plas‐
ma concentrations. Among the registered lipid-lowering drugs, only nicotinic acid has
a consistently significant Lp(a)-lowering effect, and we recently succeeded in elucidat‐
ing the mode of action of this drug. There are numerous medications in the pipeline
for the treatment of hyper-Lp(a). Among those that are currently in clinical trials,
CETP inhibitors, PCSK9 antibodies, MTP inhibitors as well as antisense oligonucleoti‐
des (ASO), such as the specific APO(a)Rx® from ISIS, which is directed against apo(a)-
mRNA and appears to be the most promising drug as it lowers Lp(a) levels by more
than 90%.
Lp(a) emerged as an important screening parameter to assess coronary atherosclerosis
risk. Its quantitation in the clinical laboratory was, for a long time, quite problematic
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since commonly accepted reference materials and standardized analytical methods
were lacking. However, newer commercial assays based on nephelometry or tur‐
bidimetry, or ELISA using monoclonal antibodies that recognize single epitopes in
apo(a), warrant comparable interlaboratory results.
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1. Introduction
Lipoprotein(a) [Lp(a)] was uncovered in 1963, and its role in atherogenesis has been a matter
of debate for many years. This was caused to a certain extent by the fact that the function of
Lp(a) was—and still is—unknown. Also, there exists no specific therapy for reducing elevated
blood levels of Lp(a). Lp(a) consists of an LDL-like core and a specific antigen, apo(a). Apo(a)
exhibits a great homology to plasminogen. For this reason, it was long believed that Lp(a) may
play a role in hemostasis and fibrinolysis. There are numerous publications dealing with the
role of Lp(a) in hemostasis (reviewed in ref. [1]) providing evidence that the atherogenicity of
Lp(a) in fact might be due to a certain extent to pathophysiological effects in fibrinolysis. These
findings, however, appear to be of little relevance for practical considerations. Of much greater
importance is the causal relationship of elevated plasma Lp(a) with the incidence of athero‐
sclerosis, coronary heart diseases and stroke [2–4]. Of note, on the other hand, are the findings
that plasma Lp(a) levels rise with age, i.e. that nonagenarians exhibit significantly higher Lp(a)
plasma levels than younger generations [5].
2. Lp(a) metabolism
The protein part of Lp(a) consists of two main components, apoB-100 and apo(a) [6]. ApoB-100,
the main component of LDL, is biosynthesized in the liver and LDL is the end-product of VLDL
catabolism. Yet, LDL also appears to be synthesized directly and secreted from the liver. Liver
LDL, however, displays a different composition from VLDL-derived LDL. Apo(a) consists of
11 unique “kringle-IV’s” (K-IV) that are highly homologous to kringle-4 of plasminogen. In
addition, apo(a) has a variable number of so-called repetitive K-IVs, which is one of the main
puzzles in the immunochemical quantification of Lp(a) (see below). In addition to the presence
of K-IVs, apo(a) possesses one kringle-V and a nonactive protease domain; further details on
the structure of apo(a) may be found in ref. [7]. The exact mode of the assembly of Lp(a) from
LDL and apo(a) might be irrelevant for Lp(a) quantifications, yet it has important implications
for the development of Lp(a)-lowering drugs and the interpretation of their mode of action.
Mixing recombinant apo(a) with LDL in the test tube and incubation for a few minutes leads
to the formation of an intact Lp(a) particle that is indistinguishable from native Lp(a). This led
to the assumption that the assembly of Lp(a) takes part outside the liver in circulating blood.
Turnover studies carried out in the laboratory of H. Dieplinger (Innsbruck), on the other hand,
revealed that the synthesis rate of protein components of Lp(a), i.e. apoB-100 and apo(a), are
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identical but distinct from the synthesis rate of apoB-100 in LDL [8]. This appears to be a strong
argument for the intracellular assembly of Lp(a).
It is well established that the black population has strikingly different plasma Lp(a) concen‐
trations compared with the white population (black individuals have the highest and Asians
have the lowest plasma Lp(a) levels [9]). In addition to these ethnic differences, there are great
differences of plasma Lp(a) levels in any ethnic group ranging from <1 mg/dl to >200 mg/dl.
This heterogeneity is caused, on one hand, by numerous polymorphisms in the apo(a)
promoter and on the other hand by the variable number of K-IV repeats: individuals with a
high copy number of K-IV have lower plasma Lp(a) levels and those with a low number copy
number have higher plasma Lp(a) levels.
3. The biosynthesis of apo(a)
The locus for the apo(a) gene is situated at chromosome 6 (6q26–q276). The biosynthesis of
apo(a) is characteristic of that for any glycoprotein, and the negative correlation of the number
of K-IV repeats with the plasma concentration has been explained by longer cellular residence
times causing a more efficient intracellular degradation of large molecular weight apo(a)
isoforms.
The rate of apo(a) biosynthesis, on the other hand, is significantly influenced by the promoter
activity and its activation by transcription factors and nuclear receptors. We provided evidence
that the apo(a) promoter contains response elements for >70 transcription factors including
HNFs, FXR, PPARs, RXR, SREBPs, CCAAT-Enhancer, IL-6 in addition to numerous others that
play important roles in the lipid and lipoprotein metabolism [10]. The presence of these
multiple transcription factor binding sites led to the assumption that the regulation of apo(a)
transcription might be complex and influenced by numerous metabolic features. Our research
group was in fact the first to characterize important response elements in the apo(a) promoter
that are key for apo(a) transcription and the abundance of apo(a) in blood plasma [10]. The
most significant response element is that of HNF4α at position –826 to –814 in the apo(a)
promoter. HNF4α βνδνγ is competed by farnesoid-X receptor (FXR), a nuclear receptor that
plays an important role in bile acid metabolism. Thus, elevated plasma bile acid levels that
activate FXR lead to a profound reduction of Lp(a) biosynthesis. These metabolic relationships
are schematically displayed in Fig. 1.
4. The Lp(a) catabolism
There exist numerous gaps not only in the understanding of Lp(a) biosynthesis but even more
so in Lp(a) catabolism. Very little is known on the site of uptake, the mode of cell binding,
internalization and intracellular degradation. In vivo studies have been performed mostly on
animals that by themselves do not produce Lp(a). These latter studies revealed that >50% of
Lp(a) is taken up by the liver and that protein degradation products are secreted into bile [11].
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Significant amounts of radioactivity from labeled Lp(a), however, were also found in kidney,
spleen, lung and pancreas, yet it is unknown whether these organs are of relevance for Lp(a)
catabolism in humans. Since the liver is the principal organ for the LDL-receptor-mediated
catabolism of apoB-containing lipoproteins, it was of interest to study this particular pathway
for Lp(a) catabolism. In vivo studies carried out in our laboratory as well as by other groups,
however, revealed that Lp(a) only has a low affinity to the LDL-R. The main argument for this
allegation is the fact that Lp(a) is catabolized in homozygous FH patients with the same rate
as compared to healthy control individuals [12]. Since pathways involved in Lp(a) catabolism
—and in particular the role of specific receptors—is of eminent importance for strategies to
develop Lp(a)-lowering drugs, many attempts have been made to identify binding proteins
(receptors) that might be specific for Lp(a). Actually there is hardly any lipoprotein receptor
that had not been found to bind Lp(a), including LRP, VLDL-R, asialo-glycoprotein receptor,
different scavenger receptors and others. Unfortunately, all these results are based on in
vitro studies that may have little relevance for the in vivo situation. One pathway that appears
to be a hot candidate for Lp(a) catabolism is the binding of apo(a) kringle to lysine (Lys)-rich
cell surface proteins. Along these lines, we actually demonstrated in previous experiments that
Figure 1. Inhibition of apo(a) transcription by bile acids. Chenodeoxycholic acid (CDCA), the FXR agonist with the
highest affinity in humans, binds and activates FXR leading to a displacement of that complex from the cytoplasm to
the nucleus. The complex interferes with HNF4α binding to DR-1, a key response element in the apo(a) promoter and
in turn silences apo(a) transcription. With permission of the Medical University of Graz (copyrights held by the MUG
Graz, Austria).
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feeding of Lys analogues such as tranexamic acid or δ-amino valeric acid to transgenic apo(a)
or Lp(a) mice increased the Lp(a) plasma levels by a factor of 1.5–2, and this correlated with a
lower cell uptake and a higher Lp(a) degradation [13].
5. Lp(a): A causal risk factor for atherosclerosis, CHD and stroke
In MedLine and other databanks, there are more than 1500 papers listed dealing with this topic.
Thus, it is almost impossible to consider all these publications in this report. Therefore, in this
article, we concentrate mainly on the most recent findings; this does not imply that older
references might be of lesser relevance. Semiquantitative measurements of Lp(a) in a Scandi‐
navian collective by the “father” of Lp(a), Kare Berg, revealed that individuals with a more
pronounced “sinking pre-β band” [= Lp(a)] is found in lipoprotein electrophoresis correlated
with the appearance of angina pectoris and CHD [14]. The first quantitative measurements of
Lp(a) were in fact carried out by rocket electrophoresis in our laboratory in cooperation with
P. Avogaro from Venice. In that case-control study, where 183 probands were included, it was
found that the relative risk (RR) of suffering from myocardial infarction (MI)—depending on
the applied cutoff value—was approximately 2-fold higher than in healthy controls [15]. This
led to the adoption of an upper cutoff value of 30 mg/dl in most subsequent studies. In our
first publication, we also could show that patients with type-IIa hyperlipoproteinemia (familial
hypercholesterolemia, FH) exhibited a 6-fold higher risk of myocardial infarction (MI). Most
of the subsequent studies that were published from various laboratories confirmed a positive
correlation of Lp(a) plasma levels with CHD and MI. Some of the studies in fact were also
negative, i.e. no relation of Lp(a) with atherosclerotic diseases could be established (for a
review, see ref. [16]). A stab in the back to Lp(a) research in fact was given in 1993 by the article
from Ridker et al. [17], who could not find any significant relation between Lp(a) and the risk
for CHD in a nested case-control evaluation in the Physician’s Health Study with almost 15,000
probands “In this prospective study of predominantly middle-aged white men, we found no
evidence of association between Lp(a) level and risk of future MI. These data do not support
the use of Lp(a) level as a screening tool to define cardiovascular risk among this population.”
These findings of Ridker et al [17] might have been based on the fact that the methodology
used for Lp(a) quantification was subject to criticism.
Some years later, Lp(a) research encountered a revival after the publication of new data from
several research groups in 2009–2011. These studies comprised >100.000 patients or probands
and, for the first time, revealed beyond any doubt a significant causal relationship between
elevated plasma Lp(a) and CHD ([2–4, 18,19]). Of note are studies from the last 3 years which
underline the significance of Lp(a) as a risk factor for atherosclerotic cardiovascular diseases:
The PROCARDIS Consortium asked the question that had been discussed for a long time,
whether different apo(a) isoforms with different number of K-IV repeats would exert differ‐
ences in their atherogenicity [20]. There were actually indications in the literature that not only
the actual plasma concentration of Lp(a) but also the size polymorphism may reflect the risk
of atherosclerosis. Thus, in the PROCARDIS study, including some 1000 patients and a similar
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number of control individuals, plasma Lp(a) concentrations were measured by latex-enhanced
immune-turbidimetry (see below) and apo(a) isoforms were assayed by SDS-polyacrylamide
gel electrophoresis followed by immune blotting, using the isoform-standard from Immuno
A.G., Vienna. Unfortunately, Immuno A.G. does not exist anymore and isoform standards are
nowadays hard to obtain. The authors of PROCARDIS calculated the odds ratio (OR) of
patients and controls between the first and last quintile before and after adjusting for the
number of K-IV repeats. In both calculations, an OR of 2.05 (p < 0.001) was found, i.e. no
difference could be observed whether the apo(a) size polymorphism was taken into consid‐
eration or not. This report appears to quite definitely conclude this debate and is proof that
Lp(a) exerts its atherogenicity through its plasma concentration and not through possible
structural differences in K-IV repeats. In an editorial to this report, F. Kronenberg (Innsbruck)
pointed out that the analysis of SNPs—in particular rs41272114, rs10455872 and rs3798220,
which exhibit the strongest association to plasma Lp(a) concentrations can neither be taken as
surrogates nor as substitutions for the number of K-IV repeats. He further pointed out that
more than half the number of individuals with isoforms containing less than 22 K-IV repeats
are not recorded by this SNP analysis mentioned above.
In a further publication by the PROCARDIS Consortium published in ATVB [21], the question
was asked as to what extent the LPA “null allele” (rs41272114) might influence the plasma
concentration of Lp(a) in heterozygous individuals and if it might be a determinant for
atherogenic risk. In this study comprising some 8000 CAD patients, an allele frequency for
rs41272114 of approximately 3% was found. Patients containing the null allele exhibited
significantly lower plasma Lp(a) levels as compared to control individuals without the
rs41272114 allele (OR 0.79; p = 0.023). According to findings from the group of G. Utermann
[22], the rs41272114 SNP represents a donor-splice site mutation leading to the biosynthesis of
a truncated apo(a) with only 7 K-IVs (K-IV 1–7) in total and no K-V or protease domain. As a
consequence of the absence of K-IV type 9, which contains the only free –SH group in apo(a)
and is responsible for the covalent binding to apoB-100, the truncated apo(a) fragments are
well secreted from the liver into the blood but do not assemble with LDL and thus are rapidly
degraded and removed from the circulation. The PROCARDIS study also proved that
individuals with only one apo(a) isoform exhibit a large variation in their plasma Lp(a)
concentrations and that there exists a sigmoid correlation between the number of K-IV repeats
and plasma Lp(a) levels. The question of the mechanism that causes this variation, however,
could not be answered by this study. The authors of the PROCARDIS Consortium claimed, on
the basis of their results, that in future epidemiological studies by SNP analysis for the
assessment of the CAD risk, the rs41272114 polymorphism must be taken into consideration
as a matter of state-of-the-art experiments.
Further support of the hypothesis published in 1981 by our group [15] indicating that Lp(a)
might be a significant risk factor for MI comes from the “Bruneck Study” comprising 826 male
and female probands [23]. In a recall survey after 15 years, it was found that the inclusion of
Lp(a) in the Framingham algorithm for the risk assessment of CHD, an improvement of 0.016
in the C-index was reached. Consideration of Lp(a) plasma levels improved the hit rate in the
prediction of CHD by 40%.
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6. Lp(a) and stroke
The question as to what extent Lp(a) might also be causally related to stroke was addressed in
numerous publications (reviewed in ref. [24]). Sultan et al. [25] recently published the results
of his meta-analysis, where he included 10 published papers dealing with ischemic stroke in
children. Setting the cutoff level for Lp(a) at 30 mg/dl, a positive association between Lp(a)
and stroke was found with a Mantel-Haenszel OR of 4.24 (p < 0.00001).
As mentioned above, the physiological function of Lp(a) is in the dark. Concerning the
pathophysiology, the work of Tsimikas et al. from San Diego is noteworthy because they
believe that the high affinity of Lp(a) for oxidized phospholipids might be responsible for its
atherogenicity [26]. Oxidized phospholipids are known to promote the synthesis of inflam‐
matory cytokines that recruit monocytes and T-lymphocytes. Monocytes differentiate to
macrophages that phagocytose oxLDL and are transformed to foam cells, hallmarks in
atherogenesis. Negatively charged phospholipids such as Ox-Phos are key components in
oxLDL and also bind a specific protein, β-2-glykoprotein-I (β2-GPI). The latter also forms a
complex with Lp(a). In a recently published paper, it was reported that the plasma levels of
Lp(a), Ox-Lp(a) and β2GP-I-Lp(a) in stroke patients were significantly higher than in controls
(124 patients vs. 64 controls). In addition, a positive correlation of these plasma parameters
with the severity of stroke was established [27]. These findings point towards the assumption
that Lp(a) might not neutralize ox-PL but in contrast boosts its atherogenic properties.
7. Medication of patients with elevated plasma Lp(a)
Although recent publications might be taken as a clear hint for the causal relationship between
elevated Lp(a) and CHD, a final proof might be only obtained from intervention studies with
Lp(a)-lowering drugs (see ref. [28]). Unfortunately, there hardly exists any drug that may
specifically lower plasma Lp(a). As a consequence of the work cited above, however, intensive
efforts have been taken to develop such therapeutic agents. In addition, any new lipid-lowering
or HDL-raising drug that is in clinical trials is checked for its potential action on Lp(a). There
exist several serious recommendations for the treatment of relevant patients (reviewed in ref.
[16]), but many of them are based on anecdotal observations, or are of little practical value or
low efficacy. As mentioned above, Lp(a) is hardly bound by the LDL-R and thus specific drugs
acting solely by increasing LDL-R activity are mostly inactive in the treatment of hyper-Lp(a)
patients. Statins that belong to this sort of drugs are therefore not the drugs of choice—and
actually there are reports that statins even may lead to an elevation of Lp(a) [29]. Unfortunately,
the pathomechanism of the LDL-raising effect of this observation is unknown.
The only current method that reduces plasma Lp(a) levels to a satisfactory extent is apheresis,
and it has been shown that lowering Lp(a) by this method reduced the CHD risk significantly
[30]. Apheresis is therefore strongly advised in the secondary prevention of patients with very
high plasma Lp(a) (>80 mg/dl).
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Another current possibility is medication with nicotinic acid or derivatives thereof. Nicotinic
acid (niacin), its amide or different retard compounds were, for a long time, in the markets of
numerous countries because of their HDL-raising properties. In addition, these compounds
reportedly reduce plasma Lp(a) by some 30% [31]. In recent studies, we succeeded to uncover
the mode of action of this drug at a molecular level: the APOA promoter contains several cAMP
response elements that impact the apo(a) transcription [32]. Nicotinic acid interferes in liver
with the binding activity of cAMP to these elements and reduces the biosynthesis of apo(a)
(see cartoon in Fig. 2).
Figure 2. Influence of nicotinic acid on apo(a) biosynthesis: Proposed mode of action. cAMP regulates apo(a) biosyn‐
thesis by binding to specific cAMP response elements in the APOA promoter. Nicotinic acid inhibits adenylate cyclase,
the key enzyme of cAMP biosynthesis in the liver and in turn lowers its intracellular concentration, leading to a lower
expression of the APOA gene. With permission of the Medical University of Graz (copyrights held by the MUG Graz,
Austria).
A major side effect of nicotinic acid is the activation of prostaglandin D2, particularly in the
skin, which causes the dilatation of blood vessels by binding to DP1 (PGD2 receptors) and in
turn causing skin flushing (red face). Thus, nicotinic acid is not very well appreciated by most
patients and, as a consequence, it was removed from the market in most countries. Another
drawback for nicotinic acid was the outcome of the HPS2-THRIVE study (http://
www.nejm.org/doi/full/10.1056/NEJMoa1300955). In this trial, 25,673 patients were treated
with a standard statin background therapy plus a nicotinic acid supplement consisting of 2 g
extended-release niacin + 400 mg of the DP1 antagonist laropiprant or a matching placebo. As
it turned out, the supplement nicotinic acid-laropiprant therapy did not reduce CHD risk but
increased the incidence of serious adverse events.
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8. Selective medication for hyper-Lp(a)
In our study cited in ref. [10], we actually found that patients suffering from extrahepatic
cholestasis exhibited very low Lp(a) plasma concentrations. After treating these patients and
curing them from cholestasis, Lp(a) levels vent up significantly. In this study, we succeeded
in pinpointing FXR as the most important repressor for apo(a) biosynthesis (see also Fig. 2).
Unfortunately, FXR is a pluripotent nuclear receptor that plays eminent roles not only in bile
acid and glucose metabolism but also influences the activity of LXR, the master regulator of
cellular cholesterol metabolism. There exist negative feedback loops not only between FXR
and LXR but also between FXR and other transcription factors, cytokines and interleukins.
Thus, the application of FXR activation must be done with great caution and may be not feasible
at all for prolonged applications. Nevertheless, such FXR agonists are in development and are
currently being tested for their action on the plasma levels of Lp(a). Phenex, a SME that
specializes on the development of antagonists and agonists of nuclear receptors, has the FXR
agonist Px-102® in clinical trials (http://www.phenex-pharma.com/pdf/PR-Phenex-Phase
%20I%20finished_5%20M%20Euros_engl.pdf). Px-102® significantly affects plasma choles‐
terol levels in laboratory animals and is also tested for its potential effect on liver tumors. No
data has been released so far on its potential effect on Lp(a).
Other selective Lp(a)-lowering agents are currently under investigation. They comprise mostly
drugs that were originally drafted to lower LDL cholesterol or increase HDL cholesterol.
Among them, inhibitors of PCSK-9, CETP, MTP and thyromimetica are worth noting.
8.1. PCSK-9 inhibitors
Recently, it has been published in Circulation that AMG145, the monoclonal antibody against
PCSK-9 from Amgen®, at a dose of 105 mg Q2W reduced plasma Lp(a) levels on average by
32% [33]. At this dose, the authors observed a reduction of plasma LDL-C and of apoB by 60%
and 50%, respectively. It must be stressed, however, that among the 626 male and female
patients, approximately half of them had Lp(a) levels below the median concentration of 43
nmol/L. Although the Lp(a)-lowering effect of AMG-145 correlated significantly with the
reduction of LDL-C, patients with low Lp(a) showed a much bigger relative reduction of Lp(a)
than patients of the 3rd or 4th Lp(a) quartile. At a dosage of 420 mg, Q4W patients of the 4th
quartile did not respond at all with a reduction of Lp(a). According to unconfirmed commu‐
nications AMG-145 might be registered in the 2nd half of 2015, yet the treatment costs will
certainly be significantly higher as compared to that of statin therapy.
In a similar study with SAR236553, the PCSK-9 antibody from Sanofi®, an average reduction
of Lp(a) of up to 28.6% was observed [34].We actually consider these trials as pilot studies as
they do not address all the questions of the mode of action of PCSK-9 inhibitors on Lp(a). It is
well known that these drugs increase the activity of LDL-R, particularly in the liver, and this
receptor has a relatively low affinity to Lp(a).




CETP stands for “cholesterol ester exchange/transfer protein.” It catalyzes the exchange of CE
and triglycerides between VLDL or LDL and HDL. In fact, many years ago, we published that
Lp(a) also serves as a substrate for CETP [35]. On theoretical grounds, CETP inhibitors should
be ideal for the treatment of stroke patients that exhibit significantly elevated Lp(a) and
reduced HDL levels [36]. The development of drugs containing the CETP inhibitors Torcetra‐
pib and Dalcetrapib has been stopped because of unwanted side effects. Anacetrapib and
Evacetrapib, on the other hand, are currently in phase II clinical trials. Concerning Anacetrapib,
it was published in several reports that it reduces Lp(a) by up to 25%, yet details of this study
are still lacking.
Further medications such as Eprotirome, a thyromimetikum, Lomitapide, an MTP inhibitor
from Aegerion, and Mipomersen, an antisense oligonucleotide targeting apoB, all reportedly
reduce Lp(a); however, it is rather uncertain that these drugs will ever be admitted for the
indication, high Lp(a).
The most promising medication, at the time being, appears to be APO(a)rx, a specific antisense
drug from ISIS®. In that respect, it is noteworthy that we published in 2001 that by RNA
interference, a 100% inhibition of the expression of ap(a) may be accomplished in transgene
apo(a) mice [39]. ISIS®, in fact, claims from a phase I study that in patients with Lp(a) of 10–
100 mg/dl, a reduction of up to 90% was reached (http://www.isispharm.com/Pipeline/
Therapeutic-Areas/Cardiovascular.htm#ISIS-APOARx). If ISIS ® succeeds in admitting their
antisense drug APO(a)rx, we consider this strategy as the most specific and effective in treating
hyper-Lp(a).
9. How and when should Lp(a) be measured
Actually, Lp(a) is not measured routinely in clinical laboratories because of the following
reasons: (i) there exists no effective treatment regime to lower plasma Lp(a); (ii) the currently
available Lp(a) assays are not standardized and results from different laboratories vary
considerably (see ref. [16]).
i. As mentioned above, very effective and partially specific Lp(a) medications are in
clinical trials and it is hoped that some of them might soon be on the market. Even if
it should take several years before such drugs are admitted, knowledge of the plasma
Lp(a) value gives additional important information to judge CHD risk. It has been
reported previously that plasma Lp(a) levels stay pretty constant over months and
years and may hardly be influenced by diet and living conditions. Systematic studies
within single individuals, however, revealed quite large fluctuations. Patients with
elevated or borderline Lp(a) values therefore should be assayed for Lp(a) at several
occasions.
ii. It is true that most commercial Lp(a) assays are not standardized, and the accuracy
and precision of these assays needs to be seriously revised. Since there is a strong
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genetic component in Lp(a) plasma levels, Lp(a) should also be measured in all
relatives of such index patients mentioned above. In addition, we advise that Lp(a)
should be measured in the plasma of all premature myocardial infarction and stroke
patients in addition to patients with borderline CHD risk because elevated Lp(a) puts
them into a higher risk group. Since a specific practicable Lp(a) therapy is currently
lacking, patients at increased CHD risk that exhibit elevated Lp(a) must be treated
quite more rigorously with conventional lipid-lowering therapy than similar patients
with low Lp(a). The monitoring of Lp(a), in addition, is advised in patients that
undergo state-of-the-art therapy but still show a progression of atherosclerosis or
vascular diseases, in all FH patients and in patients with genetic lipoprotein disorders,
in patients with low HDL or high homocysteine, or in patients with disorders of
hemostasis or fibrinolysis. Finally, we recommend assaying Lp(a) in patients with
diabetes mellitus and autoimmune diseases.
In a consensus report of the European Atherosclerosis Society, monitoring of plasma Lp(a) is
recommended in patients at a 10-year atherosclerosis risk of >3%. Particular attention should
be paid to hemodialysis patients and patients with any form of kidney disease. In kidney
disease, it is important before targeting hyperlipoproteinemias by medication to treat the
primary disease as well as possible and to concentrate on modifiable CHD risk factors such as
LDL-C, high blood pressure, smoking, blood glucose and obesity. Apheresis in addition to
nicotinic acid therapy must be considered in these patients if feasible, although evidence-based
results are still lacking.
10. What needs to be kept in mind when measuring Lp(a)
The first laboratory methods for measuring plasma Lp(a) were radial immune diffusion, rocket
electrophoresis and later nephelometry. Today, high-throughput methods are mostly request‐
ed comprising ELISE, DELFIA nephelometry and turbidimetry. In all these methods, one must
consider the fact that the molecular mass of Lp(a) and apo(a) varies quite strikingly within
large limits, that Lp(a) contains apoB-100 in addition to apo(a), that Lp(a) exhibits great
affinities to other proteins, e.g. β2-GPI, and in particular that apo(a) contains repetitive
structures: the number of repetitive K-IV repeats varies from 2 to approximately 40 or more.
This causes, in many assays, an overestimation of Lp(a) concentrations in patients with large
apo(a) isoforms and an underestimation in patients with small apo(a) isoforms. Finally, one
must consider the presence of small apo(a) fragments in plasma that are not bound to LDL.
Yet the concentration of these fragments correlates positively with Lp(a) levels. In order to
circumvent some problems in the quantitative analysis of Lp(a), ELISA and DELFIA methods
have been suggested where the capture antibody binds relatively unspecific all apo(a) isoforms
yet the detection antibody is monoclonal and recognizes only one epitope in apo(a). Other
assays use anti-apoB as a detection antibody. This, however, is biased by the fact that in
hyperlipidemic samples, one Lp(a) particle may bind additional apoB-containing lipoproteins
leading to an overestimation of plasma Lp(a) levels.
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As a consequence of these challenges, a group of experts in the field vent together that tackled
these problems by propagating various reference standards and methods. We also participated
in this survey using our in-house laboratory methods and antibodies [40]. A major problem
that came out from this study was the different reference materials used in the assays. Even
the use of the WHO/IFCC Reference Material as a common calibrator did not result in
satisfactory harmonization of Lp(a) values [41].
We consider most of the considerations, based on theoretical grounds, of little importance in
commercial routine clinical assays. There are three important questions that need to be solved:
(1) What methods are apo(a)-isoform insensitive? (2) How can be units in mg/dl be transformed
into nmol/L? (3) What are the cutoff levels to be adopted for risk stratification?
11. What needs to be considered in measuring Lp(a)?
Considering all these puzzles, we propagate the following: Our preferred commercial assays
are based on latex-enhanced immune-nephelometry or -turbidimetry. This is based on the
consideration that the size of latex particles in comparison to the size of Lp(a) is very high and
the size polymorphism of apo(a) becomes negligible. In addition, the latter methods are highly
precise and may be applied in high-throughput. ELISA and DELFIA methods may be isoform-
insensitive if monoclonal antibodies are used that recognize only one epitope on apo(a).
Another possibility that still needs confirmation is to assay apo(a) fragments in urine. In urine,
apo(a) fragments are secreted by a mechanism that has not been fully explored so far. These
fragments consist mostly of repetitive K-IV structures of different lengths and thus what is
measured accurately even by the use of polyclonal antibodies is the concentration of K-IVs,
mostly of type 2, that have been shown to correlate significantly with the plasma Lp(a)
concentration [42]. In the work cited in ref. [42], we could actually show that the discriminatory
power of urinary apo(a) fragments is at least as good—if not even better—than that of plasma
Lp(a).
12. Should Lp(a) levels be expressed as mass units or molar units?
This question is partly academic since there is, at the moment, no validated commercial assay
on the market that gives accurate and reliable molar values. One must also consider that most
of the individuals are heterozygous, i.e. they have 2 kinds of Lp(a) particles in their blood with
quite large differences in the molecular mass. In our laboratory, we use mass values since the
majority of the published epidemiological studies publish their values in mg/dl or mg/L. In
addition, the cutoff values propagated in the Consensus Report of the European Atheroscle‐
rosis Society are given in mg/dl.
Keeping in mind that not only the molecular mass but also the composition of Lp(a) varies
quite remarkably, we must think practicable for the time being. Assuming a molecular mass
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for Lp(a) of 3,150.000 Daltons, a value that sounds quite realistic on the basis of quasielastic
light-scattering data, a conversion factor of 3.17 for converting mass into molar units has been
proposed: 1 mg/dl apo(a) corresponds roughly to 3.17 nmol/L. It should be pointed out,
however, that in the US, a conversion factor of 2.5 has been proposed. This factor may be
calculated on the grounds of a molecular mass of 4 million.
What are the most realistic cutoff values? Most of the results from recent studies assumed that
Lp(a) is not a continuous risk factor but rather that a significant risk starts at a certain border
value. This in fact is not supported by any evidence-based study, yet on practical considera‐
tions, cutoff levels have been propagated. In the original study where Lp(a) was quantitatively
measured in our laboratory, we published that at a cutoff point of 30 mg/dl, the relative risk
for myocardial infarction in that particular collective was 1.75 and at a cutoff value of 50
mg/dl, the relative risk was 2.5 [15]. These values are very close to those that have been obtained
in numerous large epidemiological studies including meta-analyses of prospective trials
published by many laboratories. The European Atherosclerosis Society propagates, in a
consensus report that is mostly based on data from the Copenhagen Heart Study, a cutoff value
of 50 mg/dl, corresponding to approximately 150 nmol/L.
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